Patiromer plus spironolactone in resistant hypertension and CKD
Review of: Agarwal R, Rossignal P, Romero A, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019;394:1540–1550.
- Primary Health Care
- Health Care Quality, Access, and Evaluation
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Contributors DTB Team.
Provenance and peer review Commissioned; internally peer reviewed.